← All trials
NCT03434262
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 5, 2018
- Primary completion
- Feb 28, 2025
- Completion date
- Mar 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 108
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- St. Jude Children's HospitalLead sponsor
- NovartisCollaborator
- St. Jude Children's HospitalOverall official - principal investigator
Drugs studied
Indications studied
- Astrocytoma
- Brain Neoplasms
- Ependymoma
- Glioblastoma
- Glioma
- Medulloblastoma
- Meningioma
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neuroblastoma
- Oligodendroglioma
- Paraganglioma
- Pinealoma
- Central Nervous System Neoplasms
- Choroid Plexus Neoplasms
- Neuroectodermal Tumors, Primitive
- Neoplasms, Neuroepithelial
- Rhabdoid Tumor
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.